تاثیر لاکتوباسیلوس پلانتاروم بر روی بهبود گاستریت معده ناشی از عفونت هلیکوباکتر پیلوری در مدل موشی C57BL/6

Introduction: Helicobacter pylori has become accepted as an important human pathogen for the development of gastritis since it was first reported by marshal and warren in 1983. About half of the world human population is infected by H. pylori. Current standard therapies against H. pylori are based on the use of one proton pump inhibitor plus two or more antibiotics. The efficacy of this treatments has been decreased, mainly due to the increase of antibiotic resistance but also to side effects. So we tried to follow other therapies. The role of probiotics in the treatment of gastrointestinal infections has increased during recent decades. One of the most important groups of probiotics is lactic acid bacteria. The aim of this study was to analyse the efficacy of Lactobacillus plantarum on gastric ulcer induced by helicobacter pylori (ATCC43504). Methods: In this experiment, the mice were randomly divided into three experimental groups (ten mice in each group). Mice were inoculated with h.pylori suspension (5*1010cfus/ml) in PBS by gavage twice daily for three consecutive days. Four weeks after the last inoculation we confirmed the infection by determination of h.pylori stool Ag (ELISA) and histopathological examination. One mouse from each group sacrificed and the tissues removed. The groups were subjected to different therapies as stated, 1: without Bismuth (Bi) and Omeprazole (Om) prescription, 2: Bi, Om and Clarithromycin (Cl) and 3: Bi, Om plus 1cc of suspension of 109CFU/ml of L. plantarum. After 2 weeks, the stool was analyzed for Ag and the mice were sacrificed for evaluation of histopathologic changes. Results: Treatment with L. planratum group provided Zero titer of stool Ag and was associated with improved gastric inflammation in all subjects, similar to the clarithromycin group Conclusion: L.plantarum probiotics provides similar results as clarithromycin in terms of improvement of H. pylori infection and gastritis in C57BL/6 Mice model, without its cons of antibiotic resistance.